CRISPR Therapeutics AG - Company Profile

All the sales intelligence you need on CRISPR Therapeutics AG in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how CRISPR Therapeutics AG fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with CRISPR Therapeutics AG.

Back to companies

CRISPR Therapeutics AG: Segment Analysis

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Related keylists

Top 10 Emerging Pharmaceutical Companies in Europe in 2021 by Revenues

Business Description

CRISPR Therapeutics AG (CRISPR Therapeutics) is a biotechnology company focused on developing transformative gene-based medicines for serious human diseases. The company specialises in CRISPR-based therapeutics, utilising CRISPR/Cas9 technology for gene editing. Its primary activities include the development of therapies for genetic diseases and engineering advanced cellular therapies. CRISPR Therapeutics operates in the biotechnology industry, serving sectors such as hemoglobinopathies, oncology, autoimmune diseases, cardiovascular diseases, and diabetes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

CRISPR Therapeutics is focused on the development of novel therapies to treat hemoglobinopathies, cancer, autoimmune diseases, cardiovascular diseases, diabetes, and other diseases. The company's research and development initiatives include advancing therapies in hemoglobinopathies such as sickle cell disease and beta thalassemia, oncology including B-cell and T-cell lymphomas and renal cell carcinoma, autoimmune diseases like myositis, scleroderma, and systemic lupus erythematosus, cardiovascular diseases such as elevated lipoprotein(a), homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, severe hypertriglyceridemia, mixed dyslipidemia, and diabetes, specifically type 1 diabetes. CRISPR Therapeutics operates R&D units in Zug, Switzerland, and Boston, Massachusetts. The company has developed a broad intellectual property estate with patents expected to expire starting in 2033. The pipeline includes products for sickle cell disease, beta thalassemia, autoimmune diseases, oncology, and cardiovascular diseases. Major technology alliances include partnerships with companies like Vertex. In FY2025, the company’s R&D expenses stood at US$284.8 million.

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Who We Are

Industries We Cover

Who We Serve

Corporates

Financial Institutions

Professional Services

Other

What We Offer

Intelligence Centers

Consultancy

Marketplace